Teva launches copy version of Difflam in the UK

The UK subsidiary of Israeli generics giant Teva Pharmaceutical Industries (Nadaq: TEVA) has announced its launch in the UK of Oroeze (benzydamine 0.15% w/v Oromucosal spray, a version of brand leader's Difflam (benzydamine) from Meda Pharmaceuticals. The Oroeze Marketing Authorization holder is Focus Pharmaceuticals.

The product is indicated as a locally acting analgesic and anti-inflammatory treatment for the throat and mouth. It is especially useful for the relief of pain in traumatic conditions such as following tonsillectomy or the use of a naso-gastric tube; dental surgery. This product is available immediately in the Teva 360 livery, at a pricing £3.50 a pack, versus £3.63 for the branded product.

Kim Innes, commercial director at Teva UK, said: "As the leading supplier of generic medicines and with the widest portfolio of our competitors, Teva continues with strong product launches and patent expiries. We've already launched eighteen new products this year including ten on day-one of patent expiry."